FDA warns Trexo Robotics over unapproved robotic gait-training legs for children and design-control gaps at its Canadian plant.
What happened
FDA inspected Trexo Robotics Holdings Inc. in Mississauga, Ontario, Canada from June 3 through June 5, 2023, and also reviewed the firm's website on October 5, 2023. FDA concluded the Trexo Home and Trexo Plus devices are marketed for a new intended use - helping children with disabilities walk and stand - without an approved premarket approval (PMA) application or investigational device exemption (IDE), and without a 510(k) premarket notification. The inspection also found the firm's quality system procedures did not meet the Quality System regulation (21 CFR Part 820).
What FDA found
The firm sells the device for a use outside the exempt category and without an approved PMA or IDE, which makes it adulterated.
Section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)The firm began commercial distribution without sending FDA a 510(k) premarket notification, which makes the device misbranded.
Section 502(o) of the Act, 21 U.S.C. § 352(o); 21 CFR 807.81Design control procedures did not ensure the design process was followed or that validation on initial production units was done and documented.
21 CFR 820.30(a)Procedures did not ensure that processes which cannot be fully verified by later inspection and testing, such as the circuit board and motor tests, were validated.
21 CFR 820.75(a)Corrective and preventive action procedures did not require review of all quality data sources, such as nonconformance reports.
21 CFR 820.100(a)(1)Complaint procedures allowed complaints to be handled as feedback, so they were not checked for reporting to FDA, and some complaint investigations were not documented.
21 CFR 820.198(a)
What FDA wants
FDA tells the firm to stop activities that misbrand or adulterate the Trexo devices, including commercial distribution for the uses described. The firm must reply in writing with the specific corrections, corrective actions, supporting documentation and, if work is ongoing, a timetable.
Who should pay attention
- pediatric rehabilitation clinics and therapists considering robotic gait devices
- U.S. distributors and resellers of foreign-made medical devices
- quality teams at device startups that rely on an exempt classification
- contract manufacturers building powered rehabilitation hardware
This is a summary. Read the original letter on fda.gov.